Epigeneer GmbH has been established in Mainz, Germany, as a subsidiary of AdRegeneer AG. The new company focuses on developing transdermal patch therapies for patients with Multiple Sclerosis (MS) and other neurodegenerative diseases.

​

Building on AdRegeneer’s pioneering epigenetic platform technology, Epigeneer aims to restore lost neurological functions by promoting myelin repair. The team is committed to translating cutting-edge science into practical therapies that improve patients’ quality of life.

​

The Mainz location provides an ideal environment for scientific collaboration, clinical development, and partnership opportunities across Europe.